A comprehensive overview of the companies, science, capital, and future shaping the race to extend the healthy human lifespan.
Artificial intelligence is accelerating the science of human aging at an unprecedented pace — compressing decades of lab work into months and unlocking biological mechanisms that were once considered intractable.
Transformer models and generative AI identify novel anti-aging compounds and therapeutic targets at a scale impossible through traditional methods. Insilico Medicine became the first AI-first biotech to complete a Phase II trial and achieve a major IPO.
AI platforms are mapping which transcription factors can safely "reset" the aging clock of individual cells without inducing dangerous pluripotent states — the central bet of companies like NewLimit and Turn Bio.
Deep learning models trained on methylation, proteomics, and multi-omics data can now measure a person's biological age with high precision — creating actionable metrics for both clinical trials and consumer products.
AI platforms like Rubedo's ALEMBIC system are identifying druggable targets for clearing senescent ("zombie") cells — a root cause of age-related tissue dysfunction, inflammation, and disease.
Companies like Human Longevity Inc. use AI-driven analytics to shift care from reactive to proactive, building comprehensive health portraits that identify risks decades before symptoms emerge.
AI is uniquely capable of fusing genomics, transcriptomics, epigenomics, metabolomics, and proteomics into coherent aging signatures — a task far beyond human analytical capacity.
The convergence of AI and longevity science has been building for over a decade, reaching an inflection point in the early 2020s.
Despite extraordinary progress, the longevity field faces deep scientific, regulatory, and social challenges that will shape the pace and distribution of breakthroughs.
While average life expectancy has increased, average healthspan — years spent in good health — has remained largely static. The core mission of the field is not simply adding years, but compressing "morbidity" so that people remain healthy, cognitively sharp, and functional until very late in life. No intervention has yet demonstrated the ability to meaningfully expand healthspan in humans at scale.
The vast majority of promising longevity compounds — senolytics, NAD+ boosters, mTOR inhibitors, and partial reprogramming protocols — have demonstrated impressive results in model organisms (mice, C. elegans, yeast) but have not yet been rigorously validated in long-term human trials. The FDA has no approved indication for "aging" itself, forcing companies to target specific age-related diseases instead.
AI models for aging are only as good as their training data. Existing large-scale longitudinal datasets are overwhelmingly drawn from Western, educated, industrialized populations — introducing significant bias. Sex-specific aging differences are particularly understudied, with women typically spending a disproportionate share of their lives in poor health relative to their lifespan.
Black-box AI predictions — "this compound will extend lifespan" — are difficult to validate and even harder to approve as medical treatments. Regulatory bodies require mechanistic explanations, not just statistical predictions. Bridging the gap between AI-generated hypotheses and human-interpretable biology remains a core unsolved challenge.
Partial epigenetic reprogramming risks inducing unwanted pluripotency, dedifferentiation, or tumor formation. Determining the precise dose, duration, and target-cell specificity of reprogramming factors without triggering cancer or loss of cellular identity is arguably the hardest unsolved problem in the entire field.
Longevity medicine operates in a regulatory grey zone. There are no approved "anti-aging" indications, and the TAME trial (Metformin) is still ongoing. Access and equity present profound ethical challenges: if effective longevity therapies cost $20,000+ per year (as current premium clinics do), they risk becoming exclusive to the ultra-wealthy — deepening inequality on a generational scale.
Aging trials face an inherent problem: the most meaningful outcome (longer healthspan or lifespan) takes decades to measure. The field urgently needs validated surrogate biomarkers — biological age clocks, proteomics panels — that regulators will accept as proxies for long-term outcomes, enabling shorter, cheaper trials.
The longevity field spans AI-native drug discovery, reprogramming therapeutics, diagnostics, and consumer health — with players ranging from stealth startups to Alphabet-backed giants.
| Company | Focus Area | Key AI/Tech | Stage | Notable Facts |
|---|---|---|---|---|
| Insilico Medicine | AI Drug Discovery | Generative AI, transformer models for target ID & molecule design | Phase II / Public | First AI-first biotech IPO (HKSE, ~$293M raised). Positive Phase II results for ISM001-055 (IPF). ~$400M+ raised total. |
| Retro Biosciences | Reprogramming / Plasma | OpenAI partnership for protein engineering AI; 50× boost in iPSC efficiency | Pre-clinical | Backed by Sam Altman ($180M). Partnered with OpenAI in early 2025. Focuses on plasma dilution, autophagy, and cellular reprogramming. |
| Altos Labs | Epigenetic Reprogramming | Partial reprogramming using Yamanaka factors + AI analysis | Pre-clinical | Largest longevity biotech launch in history (~$3B). Backed by Jeff Bezos, Yuri Milner. Nobel laureates on staff. |
| NewLimit | Epigenetic Reprogramming | Proprietary AI to map reprogramming factors at single-cell resolution | Late Pre-clinical | Co-founded by Coinbase CEO Brian Armstrong. ~$105M Series A. Eli Lilly invested in Series B extension. "Close" to clinic-ready therapies as of late 2025. |
| Calico Life Sciences | Aging Biology Research | ML-driven multi-omics; aging mechanism research | Pre-clinical / Research | Alphabet (Google) subsidiary. $1.5B AbbVie partnership ended Nov 2025. Long-horizon research culture. |
| Rubedo Life Sciences | Senolytics | ALEMBIC AI platform identifies senescent cell drug targets | Pre-clinical | Backed by Khosla Ventures. Targeting tissue-specific senescent cell clearance. |
| BioAge Labs | AI Drug Discovery | AI-powered biobank analysis to identify aging drug targets | Phase II / Public | IPO September 2024 ($198M raised). $170M Series D prior. Backed by a16z Bio. |
| Human Longevity Inc. | Precision Health / Diagnostics | AI-driven predictive analytics (Human Longevity Lab) | Commercial | Founded by J. Craig Venter. Largest human whole-genome database. Shifts medicine from reactive to proactive care. $21,500/yr clinic offering. |
| Shift Bioscience | Reprogramming | Generative AI + biological aging clock → cell simulation platform | Pre-clinical | Predicts gene sets most likely to safely rejuvenate specific cell types. Targets age-related diseases without inducing pluripotency. |
| Junevity (+ Ro5) | AI Drug Discovery / siRNA | RESET platform; large-scale human data + AI for transcription factor ID | Pre-clinical | Acquired AI drug discovery company Ro5. Struck 2025 deal with OpenAI for stem cell protein engineering. |
| Life Biosciences | Reprogramming (Ophthalmology) | ER-100 epigenetic reprogramming therapy | Phase I (2026) | Initiated first-in-human trials for ER-100 in optic neuropathies Q1 2026. Among the first reprogramming therapies in the clinic. |
| Hevolution Foundation | Funding / Research Enablement | AI-enabled longevity research grants; data infrastructure | Active | Saudi-backed nonprofit deploying $1B/year into longevity science globally. Identified AI data gaps as a core bottleneck. |
| Fountain Life | Longevity Clinics | AI-integrated diagnostics, whole-body imaging, biomarker panels | Commercial | Premium longevity clinic ($21,500/yr membership). Co-founded by Tony Robbins and Peter Diamandis. Backed by major family offices. |
| Function Health | Consumer Diagnostics | AI-powered blood testing (100+ biomarkers) with interpretation | Commercial (Scale) | Backed by a16z Bio. Signals mainstream acceptance of healthspan monitoring. Rapidly growing consumer base. |
The longevity industry spans supplements, therapeutics, diagnostics, clinics, and digital health — with the overall market growing at a steady 8%+ CAGR and the high-value therapeutics segment growing significantly faster.
CAGR: 8.18% (2026–2031). Broader anti-aging market (including cosmetics) exceeds $85B. Source: Mordor Intelligence, SNS Insider, New Market Pitch.
Therapeutics carries the highest growth potential. Cellular reprogramming companies capture ~50% of all VC funding. Source: New Market Pitch, Q4 2025.
Key Insight: The average longevity VC deal size reached $56.6M in 2025, with a median of $27.3M. Q4 2025 saw a dramatic funding surge — $554M across 9 deals, a 900% jump from the prior quarter — signaling renewed institutional conviction after the broader biotech downturn of 2022–2023. North America dominates with 97.8% of all disclosed capital in the past 12 months.
Longevity has attracted a distinctive investor mix: traditional life science VCs, tech-world billionaires making personal bets, sovereign wealth foundations, and increasingly, large pharma strategic investments.
The most active institutional investor in longevity with 10+ deals across 2022–2025. Lead positions in Turn Biotechnologies, Rejuvenation Technologies, Rubedo Life Sciences, Circulate Health, Viome, and NewLimit. Vinod Khosla has made aging a core investment thesis, publicly advocating for a world where 80 is the new 40.
Participated in at least 4 major longevity deals including BioAge Labs, Function Health, and Arda Therapeutics. Their investment in Function Health signals mainstream institutional acceptance of healthspan optimization as a commercial category.
OpenAI CEO invested $180M of personal capital in Retro Biosciences. The subsequent OpenAI–Retro partnership brought frontier AI capabilities directly into longevity biology, demonstrating how tech-world principals are blurring the line between investor and strategic partner.
Co-led the ~$3B launch of Altos Labs in 2021 — the largest single biotech launch in history. Both have made aging research a personal philanthropic and investment priority, attracting Nobel laureates and top scientists with unusually long research horizons.
Saudi-backed nonprofit deploying $1B per year into global longevity science. Funds both early-stage academic research and later-stage clinical trials. Serves as a "market maker" for the field by funding research that commercial investors won't yet touch, including the landmark TAME (Metformin) aging trial.
Invested in NewLimit's Series B extension in 2025, signaling that large pharma is beginning to treat longevity biotech as a legitimate pipeline source rather than fringe science. Lilly's investment follows their massive bet on GLP-1 obesity drugs — another "metabolic aging" category.
Launched the PROSPR program in December 2024 with the explicit goal of extending American healthspan by 20 years. Government-backed funding de-risks early research and creates a political mandate for longevity science, likely to catalyze further institutional investment.
Funds Calico Life Sciences with a long-horizon mission to understand the biology of aging. While the AbbVie partnership ended in 2025, Alphabet continues to back the venture as a research entity, with Google DeepMind's AlphaFold advances directly enabling the field.
Funding Trend: Deal size climbed from a median of ~$20M during the 2023 biotech winter to $52M in 2024 and $69M average by 2025. The funding base is increasingly bifurcated: a small number of very large bets (Altos, Retro) alongside a large number of $20–50M seed/Series A rounds in AI-native longevity startups. Geographic concentration remains extreme — North America accounted for 97.8% of disclosed longevity capital in the 12 months ending April 2026.
The convergence of AI, genomics, and molecular biology is approaching an inflection point. Here is what researchers, investors, and technologists expect over the next decade.
Life Biosciences' ER-100 (optic neuropathy) and several other Phase I reprogramming trials will generate first-in-human safety and efficacy data — the most watched clinical readout in longevity history.
Expect the FDA and international regulators to begin accepting validated biological age biomarkers (epigenetic clocks, proteomic panels) as surrogate endpoints in aging trials — dramatically reducing trial costs and duration.
Insilico Medicine's pipeline and several competitors will advance AI-discovered compounds into Phase III trials. If positive, these will be the first drugs approved for age-related conditions discovered entirely by artificial intelligence.
As diagnostics costs fall and insurance coverage expands, longevity clinics (currently $20K+/yr) will become accessible at $1,000–$5,000/yr price points, reaching tens of millions of consumers rather than the current elite clientele.
Semaglutide (Ozempic/Wegovy) and next-generation GLP-1 drugs are already showing unexpected longevity signals in cardiovascular, neurological, and metabolic aging. The $105B obesity drug market will increasingly overlap with longevity therapeutics.
If reprogramming trials succeed, therapies that reverse biological age by 5–15 years in specific tissues (eye, muscle, brain) could reach approval. AI will be central to identifying patient populations, personalizing dosing, and monitoring treatment response in real time.
Continuous wearable sensors (glucose, HRV, proteomics chips) will generate population-scale longitudinal aging data — the missing ingredient for training the next generation of aging AI models. This will dramatically accelerate both research and consumer personalization.
The endgame is not a single drug but a personalized "longevity stack" — combining senolytics, reprogramming, metabolic optimization, and immune rejuvenation — designed by AI and refined over a lifetime. Some researchers project that people alive in 2035 could have access to treatments designed to extend healthy lifespan by 20+ years.
The Central Bet: The longevity field is betting that aging is not an immutable fact of biology but a programmable process — and that AI gives us, for the first time, sufficient computational power to decode and intervene in it. Whether the first wave of reprogramming, senolytic, and AI-discovered drugs delivers on this promise will likely be answered by the early 2030s. The scientific and financial infrastructure being built today is without precedent in biomedical history.